DMAC vs DRI · $157.4M cap vs P/E 22, rev $12.08B
DiaMedica Therapeutics Inc (DMAC) versus Darden Restaurants Inc (DRI) — a side-by-side from cached financials, not a winner call.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
Darden Restaurants Inc (DRI) is a restaurants company listed on NYSE.
DMAC does not have a complete income-statement cache yet.
Latest reported DRI revenue for 2025-05-25 was $12.08B. Net income was $1.05B. Revenue was up 6.0% from 2024-05-26 to 2025-05-25. DRI currently screens at market cap $24.20B and trailing P/E 22.3.
DMAC currently screens at market cap $157.4M. DRI currently screens at market cap $24.20B and trailing P/E 22.3.
Not investment advice. Open the DMAC and DRI stock pages for the full models.
Not investment advice.